Novigenix
17.1.2024 08:02:15 CET | ACCESS Newswire | Press release
GENEVA, SWITZERLAND / ACCESSWIRE / January 17, 2024 / With cancer projected to escalate to 29 million cases by 2040[1], Novigenix, a pioneer in AI healthcare solutions, is rewriting the rules of cancer care. Their newest innovation, LITOSeek™, is primed to reshape drug development, offering a transformative leap forward.
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.Personalized Cancer Treatment: Breaking Barriers
Every cancer is as unique as the person it affects. Tumors are in continuous dynamic interplay with the patient's immune defenses and are adept at subverting and escaping immune control. Novigenix is on a mission to improve the cancer treatment landscape, leveraging advanced AI and RNA analysis from a routine blood draw to provide more precise insights into patient immune responses to cancer treatments, compared to conventional DNA liquid biopsies that evaluate tumor evolution through circulating tumor DNA (ctDNA). Insights into the precise dynamic of patient immune response thus pave the way for superior therapeutic discoveries in the field.
Empowering Biopharma: Unveiling LITOSeek™ at Precision Medicine World Conference
On January 24th at the Precision Medicine World Conference in Silicon Valley, Novigenix will debut LITOSeek™, a groundbreaking solution designed to expedite drug development for biopharma companies.
AI and RNA Analysis: Pioneering Healthcare Transformation
With a decade-long track record, Novigenix successfully launched Colox® blood test in Switzerland, powered by AI and RNA analysis to detect early-stage colon cancer, marking a significant departure from invasive colonoscopy procedures. By aggregating data from diverse colon cancer patients, Novigenix identified immune system biomarkers crucial for early-stage detection, enhancing treatment outcomes.
Dr. Brian Hashemi, Novigenix's CEO and Chairman, emphasized, "Our experience with Colox® underscores the potential of AI RNA analysis. Ongoing studies across various cancer types have fuelled our Knowledge Base to uncover comprehensive sets of biomarkers via liquid biopsy and AI RNA analysis. Our validated immunotherapy response biomarkers provide early prediction of patient response and we invite biopharma companies to leverage our platform for more efficient and effective drug development."
Professor Pedro Romero, M.D. Chief Medical & Scientific Officer of Novigenix, and Founding Chief Editor of the Journal of Immunotherapy of Cancer, highlights the importance of patient immune response in the development of novel therapies: "AI RNA analysis is poised to revolutionize healthcare, accelerating conventional experimental drug development with data-driven precision immune response prediction. By swiftly analyzing systemic immune responses, AI compresses analysis times, expediting traditional drug development and powering discovery of novel therapy targets."
A Team Dedicated to the Future of Cancer Care
With over 20 Ph.D.-level scientists focused on the development of the LITOSeek™ platform and advancing next-generation liquid biopsy solutions, Novigenix is pioneering precision immunology to help transform cancer treatment paradigms for better patient outcomes.
#Ends#
[1] https://canceratlas.cancer.org/the-burden/the-burden-of-cancer/
Contact Information
Edwin Shankar
edwin.shankar@leidar.com
SOURCE: Novigenix
To view this piece of content from stats.newswire.com, please give your consent at the top of this page.View the original press release on newswire.com.
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
From Retrofit to AI: Akkodis Strengthens Digital Innovation Through Industrial Aerospace Applications at ILA Berlin 202610.6.2026 06:45:00 CEST | Press release
At ILA Berlin 2026, Akkodis will showcase concrete applications in digital engineering, AI-driven analytics and industrial execution across the entire aerospace lifecycle - from initial digital design to real-world aerospace applications. BERLIN, DE / ACCESS Newswire / June 10, 2026 / Akkodis, a global leader in digital engineering consulting and part of the Adecco Group, demonstrates how digital development, artificial intelligence and industrial execution come together to bring new solutions into aerospace applications faster at ILA Berlin 2026. Image: Akkodis at ILA Berlin 2026. Source: AkkodisIn 2026, the aerospace and defense sector is being shaped by strong growth and sustained long-term demand, supported by continued investment in innovation and next-generation technologies. At the same time, increasing pressures on efficiency, availability and sustainability are driving a shift toward solutions that can be rapidly integrated and scaled. At the center of Akkodis' presence is a n
Northfield Announces Change of Corporate Name to Juno International Corporation9.6.2026 21:45:00 CEST | Press release
TORONTO, ON / ACCESS Newswire / June 9, 2026 / Northfield Capital Corporation (TSXV:NFD.A) (the "Corporation") today announced that it will change its corporate name to "Juno International Corporation" effective Thursday, June 11, 2026 (the "Name Change"). The trading symbol for the Corporation's class A restricted voting shares (the "Shares") will change to "JUN.A" following the completion of the Name Change. Trading of the Shares on the TSX Venture Exchange under the new name will commence at the open of markets on Thursday, June 11, 2026. There is no change in the capitalization of the Corporation in connection with the Name Change. No action is required by existing shareholders of the Corporation with respect to the Name Change. Outstanding certificates and Direct Registration Statement Advices with respect to the Shares do not need to be exchanged. Upon completion of the Name Change, the Company's new CUSIP number for the Shares will be 482045101 and its new ISIN number will be CA
WLF Energy and Farasis Energy Sign Strategic Partnership Agreement to Accelerate Next-Generation Energy Storage Solutions Globally9.6.2026 15:20:00 CEST | Press release
Partnership combines Farasis Energy's advanced battery technology leadership with WLF Energy's integrated energy platform, AI-driven optimization capabilities, and global deployment strategy STUTTGART, GERMANY / ACCESS Newswire / June 9, 2026 / WLF Energy and Farasis Energy today announced the signing of a Strategic Partnership Agreement to jointly develop, industrialize, and commercialize next-generation battery technologies and energy storage products for global markets. The partnership establishes a long-term framework for collaboration across battery cell technology, battery systems, energy management software, artificial intelligence, and large-scale deployment of energy storage solutions. Together, both companies aim to accelerate the transition toward more affordable, resilient, and sustainable energy infrastructure worldwide. The agreement combines Farasis Energy's extensive experience in advanced battery technology development and manufacturing with WLF Energy's integrated tec
WLF Energy Launches as Europe's Fast, Clean, Bold New Vertically Integrated Clean Energy Champion; Built to Power a Continent9.6.2026 13:30:00 CEST | Press release
Energy platform goes public at The Battery Show Stuttgart, targeting sub-10ct/kWh clean energy for everyone in Europe - and laying the foundation for the continent's energy independence in the decade ahead. STUTTGART, DE / ACCESS Newswire / June 9, 2026 / WLF Energy GmbH today made its public debut at The Battery Show Europe in Stuttgart, unveiling its fully integrated clean-energy platform and long-term mission to deliver affordable, intelligent and sovereign energy infrastructure at global scale. The announcement was delivered by CEO and Chairman Sebastian Wolf, marking the company's first public appearance before a global audience of battery industry leaders, technology innovators and energy investors. The debut signals the arrival of a new kind of European energy company - one designed to integrate generation, storage, intelligence and energy trading into a single platform capable of making clean power the most affordable form of energy in Europe. Founded in 2026, WLF Energy is dev
U.S. Polo Assn. Returns to Downtown London as Official Apparel and Jersey Partner of Chestertons Polo in the Park9.6.2026 13:00:00 CEST | Press release
Over 30,000 Attendees Celebrate the Sport of Polo and ‘An Icon Born from the Game' WEST PALM BEACH, FL AND LONDON, UK / ACCESS Newswire / June 9, 2026 / U.S. Polo Assn., the official sports brand of the United States Polo Association (USPA), returned for the third consecutive year as the Official Apparel and Jersey Partner of Chestertons Polo in the Park, bringing together world-class competition, sport-inspired fashion, thrilling entertainment, and memorable lifestyle experiences for one of London's most anticipated summer sporting events. Held June 5-7, 2026, at Hurlingham Park in central London, the three-day festival welcomed more than 30,000 attendees for a celebration of the sport of polo in one of the world's most iconic urban settings. The Red Sea Global Team Riyadh and the Disney+ Team Rivals fighting for the ball at Chestertons Polo in the Park As the Official Apparel and Jersey Partner, U.S. Polo Assn. outfitted all teams throughout the tournament with custom-designed perfor
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom